MX2018003023A - Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular. - Google Patents
Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular.Info
- Publication number
- MX2018003023A MX2018003023A MX2018003023A MX2018003023A MX2018003023A MX 2018003023 A MX2018003023 A MX 2018003023A MX 2018003023 A MX2018003023 A MX 2018003023A MX 2018003023 A MX2018003023 A MX 2018003023A MX 2018003023 A MX2018003023 A MX 2018003023A
- Authority
- MX
- Mexico
- Prior art keywords
- patient population
- methods
- treatment
- particular patient
- neurodegenerative disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Aquí se describen métodos para tratar, mejorar y/o prevenir la enfermedad de Alzheimer en una población de pacientes específica utilizando tramiprosato, ácido valil-3-amino-1-propansulfónico o una sal farmacéuticamente aceptable del mismo basado en una combinación de estado APOE4 y gravedad de la enfermedad.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562216404P | 2015-09-10 | 2015-09-10 | |
| US201662290287P | 2016-02-02 | 2016-02-02 | |
| US201662302027P | 2016-03-01 | 2016-03-01 | |
| US201662365809P | 2016-07-22 | 2016-07-22 | |
| PCT/US2016/051091 WO2017044840A1 (en) | 2015-09-10 | 2016-09-09 | Methods of treating neurodegenerative disorders in a particular patient population |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018003023A true MX2018003023A (es) | 2018-06-06 |
| MX392677B MX392677B (es) | 2025-03-24 |
Family
ID=58240195
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018003023A MX392677B (es) | 2015-09-10 | 2016-09-09 | Composiciones para usarse en el tratamiento de trastornos neurodegenerativos en una población particular de pacientes. |
| MX2022003128A MX2022003128A (es) | 2015-09-10 | 2018-03-09 | Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003128A MX2022003128A (es) | 2015-09-10 | 2018-03-09 | Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular. |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11191742B2 (es) |
| EP (2) | EP4275750A3 (es) |
| JP (4) | JP6789579B2 (es) |
| KR (2) | KR102547164B1 (es) |
| CN (3) | CN116712423A (es) |
| AU (1) | AU2016319107B2 (es) |
| CA (1) | CA2997376C (es) |
| DK (1) | DK3347002T3 (es) |
| ES (1) | ES2952727T3 (es) |
| FI (1) | FI3347002T3 (es) |
| HR (1) | HRP20230809T1 (es) |
| HU (1) | HUE062511T2 (es) |
| LT (1) | LT3347002T (es) |
| MD (1) | MD3347002T2 (es) |
| MX (2) | MX392677B (es) |
| PL (1) | PL3347002T3 (es) |
| PT (1) | PT3347002T (es) |
| RS (1) | RS64481B1 (es) |
| SI (1) | SI3347002T1 (es) |
| SM (1) | SMT202300250T1 (es) |
| WO (1) | WO2017044840A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3119911T3 (fi) | 2014-03-21 | 2023-09-27 | Alzheon Inc | Yhdisteitä käytettäväksi alzheimerin taudin hoitamisessa apoe4+/+-potilaissa |
| PT3347002T (pt) * | 2015-09-10 | 2023-07-27 | Alzheon Inc | Tratamento de doença de alzheimer numa população particular de pacientes |
| CN108623501B (zh) | 2017-03-21 | 2022-04-19 | 润佳（苏州）医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸衍生物及其用途 |
| CN110003058B (zh) | 2018-01-04 | 2022-01-25 | 润佳（苏州）医药科技有限公司 | 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途 |
| DK3829568T3 (en) | 2018-08-01 | 2023-12-18 | Alzheon Inc | Sulfopropanoic acid derivatives for treating neurodegenerative disorders |
| JP7573512B2 (ja) * | 2018-08-01 | 2024-10-25 | アルツェオン・インコーポレーテッド | 神経変性障害を治療するための方法 |
| CN111170901A (zh) * | 2018-11-13 | 2020-05-19 | 润佳（苏州）医药科技有限公司 | 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途 |
| WO2020257159A1 (en) | 2019-06-17 | 2020-12-24 | Alzheon, Inc. | Methods for treating neurodegenerative disorders |
| CN112791078B (zh) | 2019-11-13 | 2022-12-06 | 润佳（苏州）医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途 |
| AU2022405026A1 (en) * | 2021-12-09 | 2024-06-20 | Alzheon, Inc. | Alz-801 for use in treating alzheimer's disease |
| JP2025504199A (ja) * | 2022-02-07 | 2025-02-06 | アルツェオン・インコーポレーテッド | Ｃｏｖｉｄ－１９関連神経症状の治療に使用するためのａｌｚ－８０１ |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| FI951701A7 (fi) | 1992-10-13 | 1995-04-10 | Univ Duke | Menetelmät Alzheimerin taudin tunnistamiseksi |
| US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US20060079578A1 (en) | 2003-06-23 | 2006-04-13 | Julie Laurin | Pharmaceutical formulations of amyloid inhibiting compounds |
| US20070010573A1 (en) | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| US20050142191A1 (en) | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| EP1664601B1 (en) | 2003-08-11 | 2016-10-12 | California Institute Of Technology | Microfluidic large scale integration |
| US20060251714A1 (en) * | 2005-04-12 | 2006-11-09 | Julie Laurin | Pharmaceutical formulations of amyloid inhibiting compounds |
| PL3851447T3 (pl) | 2006-10-12 | 2024-03-04 | Bellus Health Inc. | Sposoby, związki, kompozycje i nośniki dostarczające kwas 3-amino-1-propanosulfonowy |
| BRPI0719379A2 (pt) | 2006-11-24 | 2014-02-11 | Ac Immune Sa | Composto, composição farmacêutica, uso de composto, mistura, métodos para coletar dados para o diagnóstico de uma doença ou condição associada com amilóide em uma amostra ou um paciente, para determinar a extensão da carga de placa amiloidogênica em um tecido e/ou um fluido corporal, para coletar dados para determinar a predisposição a uma doença ou condição associada com amilóide em um paciente, para coletar dados para monitorar a doença residual mínima em um paciente seguindo o tratamento com um anticorpo ou uma composição de vacina e para coletar dados para predizer a responsividade de um paciente sendo tratado com um anticorpo ou uma composição de vacina, e, kit de teste |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| EP2322163A1 (en) * | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
| WO2012006329A2 (en) | 2010-07-06 | 2012-01-12 | Genomind, Llc | Apoe4 and apoj biomarker-based prevention and treatment of dementia |
| DK2605655T3 (en) | 2010-08-19 | 2019-02-04 | Buck Institute For Age Res | METHODS OF TREATING SMALL COGNITIVE DISABILITY (MCI) AND RELATED DISORDERS |
| US20150118231A1 (en) * | 2012-05-08 | 2015-04-30 | Ramot At Tel-Aviv University Ltd. | Apoe4 antibodies for treatment of neurodegenerative conditions |
| EP3552624A1 (en) | 2013-05-06 | 2019-10-16 | Baxalta Incorporated | Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g |
| KR20240094017A (ko) | 2014-02-08 | 2024-06-24 | 제넨테크, 인크. | 알츠하이머 질환을 치료하는 방법 |
| FI3119911T3 (fi) | 2014-03-21 | 2023-09-27 | Alzheon Inc | Yhdisteitä käytettäväksi alzheimerin taudin hoitamisessa apoe4+/+-potilaissa |
| PT3347002T (pt) * | 2015-09-10 | 2023-07-27 | Alzheon Inc | Tratamento de doença de alzheimer numa população particular de pacientes |
-
2016
- 2016-09-09 PT PT168451813T patent/PT3347002T/pt unknown
- 2016-09-09 PL PL16845181.3T patent/PL3347002T3/pl unknown
- 2016-09-09 MX MX2018003023A patent/MX392677B/es unknown
- 2016-09-09 FI FIEP16845181.3T patent/FI3347002T3/fi active
- 2016-09-09 CA CA2997376A patent/CA2997376C/en active Active
- 2016-09-09 EP EP23176559.5A patent/EP4275750A3/en active Pending
- 2016-09-09 US US15/758,405 patent/US11191742B2/en active Active
- 2016-09-09 KR KR1020227009418A patent/KR102547164B1/ko active Active
- 2016-09-09 SM SM20230250T patent/SMT202300250T1/it unknown
- 2016-09-09 CN CN202310582394.5A patent/CN116712423A/zh active Pending
- 2016-09-09 WO PCT/US2016/051091 patent/WO2017044840A1/en not_active Ceased
- 2016-09-09 SI SI201631729T patent/SI3347002T1/sl unknown
- 2016-09-09 ES ES16845181T patent/ES2952727T3/es active Active
- 2016-09-09 HU HUE16845181A patent/HUE062511T2/hu unknown
- 2016-09-09 AU AU2016319107A patent/AU2016319107B2/en active Active
- 2016-09-09 JP JP2018512564A patent/JP6789579B2/ja active Active
- 2016-09-09 LT LTEPPCT/US2016/051091T patent/LT3347002T/lt unknown
- 2016-09-09 DK DK16845181.3T patent/DK3347002T3/da active
- 2016-09-09 CN CN201680052760.4A patent/CN108289870A/zh active Pending
- 2016-09-09 CN CN202310582365.9A patent/CN116712422A/zh active Pending
- 2016-09-09 RS RS20230603A patent/RS64481B1/sr unknown
- 2016-09-09 EP EP16845181.3A patent/EP3347002B1/en active Active
- 2016-09-09 KR KR1020187009381A patent/KR102412997B1/ko active Active
- 2016-09-09 HR HRP20230809TT patent/HRP20230809T1/hr unknown
- 2016-09-09 MD MDE20180700T patent/MD3347002T2/ro unknown
-
2018
- 2018-03-09 MX MX2022003128A patent/MX2022003128A/es unknown
-
2020
- 2020-09-28 JP JP2020161995A patent/JP7128536B2/ja active Active
-
2021
- 2021-09-17 US US17/477,886 patent/US20220096406A1/en not_active Abandoned
-
2022
- 2022-08-12 JP JP2022128786A patent/JP2022145949A/ja active Pending
-
2023
- 2023-09-06 US US18/462,238 patent/US20230414541A1/en active Pending
-
2025
- 2025-02-17 JP JP2025023627A patent/JP2025065545A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018003023A (es) | Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular. | |
| MX2024010140A (es) | Nuevos metodos. | |
| CY1121826T1 (el) | Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson | |
| MX385332B (es) | Moduladores de ror-gamma. | |
| MX2021012547A (es) | Metodos y composiciones para exterminar celulas senescentes y para tratar enfermedades y trastornos asociados con la senectud. | |
| JP2016515522A5 (es) | ||
| EA201890111A1 (ru) | Замещенные производные оксопиридина | |
| MX383499B (es) | Agentes terapeuticos para enfermedades neurodegenerativas | |
| BR112016018170A2 (pt) | métodos para tratar doença de alzheimer | |
| EA201691516A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
| MX2022007221A (es) | Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos. | |
| MX384429B (es) | Formulaciones de aminoácidos de liberación modificada administradas por vía oral. | |
| WO2015143447A3 (en) | Methods for treating neurological disorders | |
| EA201790563A8 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
| MX378940B (es) | Trastornos neurodegenerativos. | |
| WO2016057413A3 (en) | Inhibitors of lysine gingipain | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| WO2016029136A8 (en) | 3-amidobenzamides and uses thereof for increasing cellular levels of a3g | |
| CY1124492T1 (el) | 7-υποκατεστημενα 1-αρυλο-ναφθυριδιν-3-καρβοξαμιδια και η χρηση αυτων | |
| LT3458045T (lt) | Ebselenas, skirtas naudoti menjero ligos gydymui | |
| LT3413870T (lt) | Igmesinas, skirtas panaudoti alzheimerio ligos gydymui | |
| EA201792603A1 (ru) | Ангиогенез с использованием стимулированных плацентарных стволовых клеток | |
| MX2019001804A (es) | Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos. | |
| WO2016182812A8 (en) | Activation of neuronal store-operated calcium entry pathway for the treatment of alzheimer's disease | |
| CL2018001633A1 (es) | Composiciones de benzofenonas polihidroxiladas y métodos para el tratamiento de trastornos neurodegenerativos |